MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
📊 Key Statistics
Market Cap$87M
P/E Ratio—
EPS (TTM)—
EPS YoY—
Revenue YoY—
Float—
Short Float %—
Inst. Ownership—
Sector RS—
📈 Fundamentals
ROE—
ROIC—
ROA—
Current Ratio—
Debt/Equity—
Gross Margin—
Net Margin—
Dividend Yield—
Next Earnings—
⚡ Options Summary
Call OI—
Put OI—
P/C Ratio (OI)—
Gamma Environment—
Max Pain—
Call Wall—
Put Wall—
🎯 Analyst Estimates
Consensus Target—
High Target—
Low Target—
Analysts—
Upside/Downside—
📋 Quarterly Financials
| Period |
Revenue |
Rev YoY |
EPS |
EPS YoY |
Gross Margin |
🔥 Recent Options Flow
| Type | Strike | Exp | Size | Premium | Time |
🏛️ Institutional Trades
| Type | Price | Size | Value | Venue | Time |
🏦 Top Institutional Holders
| Institution | Shares | Value | % of Class |